OCULAR THERAPEUTIX, INC (OCUL) Operating Margin
- Operating margin · 12 months: Value -603.03%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -603.03% | Operating income / revenue. Period ending 2026-06-30. $-313.91M ÷ $52.05M × 100 ≈ -603.03% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -313.91M USD | Operating Income (Loss) |
| Revenue | 52.05M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 6.71M USD | Cost of Goods and Services Sold |
| Research and development | 223.51M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-313.91M | $52.05M | $6.71M | $223.51M | (m) | -603.03% |
| 2026-03-31 | $-299.44M | $52.04M | $6.64M | $220.45M | (m) | -575.43% |
| 2025-12-31 | $-270.02M | $51.95M | $6.57M | $197.10M | (m) | -519.75% |
| 2025-09-30 | $-250.83M | $55.78M | $6.21M | $187.28M | (m) | -449.66% |
| 2025-06-30 | $-228.13M | $56.66M | $6.00M | $171.98M | (m) | -402.61% |
| 2025-03-31 | $-204.08M | $59.65M | $5.56M | $149.76M | (m) | -342.15% |
| 2024-12-31 | $-171.78M | $63.72M | $5.63M | $127.64M | (m) | -269.57% |
| 2024-09-30 | $-141.25M | $61.44M | $5.78M | $102.84M | (m) | -229.90% |
| 2024-06-30 | $-114.47M | $61.10M | $5.60M | $80.81M | (m) | -187.36% |
| 2024-03-31 | $-91.45M | $59.84M | $5.39M | $67.04M | (m) | -152.82% |
| 2023-12-31 | $-82.38M | $58.44M | $5.28M | $61.05M | (m) | -140.96% |
| 2023-09-30 | $-81.69M | $57.72M | $4.91M | $58.40M | (m) | -141.54% |
| 2023-06-30 | $-84.03M | $54.60M | $4.60M | $57.10M | (m) | -153.89% |
| 2023-03-31 | $-83.37M | $51.68M | $4.45M | $55.11M | (m) | -161.32% |
| 2022-12-31 | $-78.65M | $51.49M | $4.54M | $53.46M | (m) | -152.74% |
| 2022-09-30 | $-77.34M | $49.73M | $4.64M | $52.50M | (m) | -155.53% |
| 2022-06-30 | $-75.33M | $49.91M | $4.87M | $51.50M | (m) | -150.91% |
| 2022-03-31 | $-75.64M | $49.37M | $4.81M | $52.26M | (m) | -153.22% |
| 2021-12-31 | $-78.04M | $43.52M | $4.41M | $50.08M | (m) | -179.30% |
| 2021-09-30 | $-74.33M | $38.56M | $3.98M | $45.13M | (m) | -192.75% |
| 2021-06-30 | $-68.81M | $32.29M | $3.12M | $39.36M | (m) | -213.12% |
| 2021-03-31 | $-66.46M | $22.14M | $2.16M | $33.52M | (m) | -300.24% |
| 2020-12-31 | $-62.85M | $17.40M | $2.08M | $28.69M | (m) | -361.13% |
| 2020-09-30 | $-69.91M | $12.31M | $2.24M | $31.20M | (m) | -567.87% |
| 2020-06-30 | $-79.04M | $7.26M | $2.60M | $34.48M | (m) | -1088.30% |
| 2020-03-31 | $-82.76M | $6.34M | $3.02M | $35.87M | (m) | -1304.51% |
| 2019-12-31 | $-85.80M | $4.23M | $2.33M | $41.09M | (m) | -2029.86% |
| 2019-09-30 | $-81.68M | $2.48M | (m) | $41.22M | (m) | -3300.36% |
| 2019-06-30 | $-73.36M | $2.14M | (m) | $40.67M | (m) | -3421.46% |
| 2019-03-31 | $-65.32M | $2.14M | (m) | $40.01M | (m) | -3049.53% |
| 2018-12-31 | $-59.12M | $1.99M | (m) | $36.91M | (m) | -2970.75% |
| 2018-09-30 | $-54.55M | $1.97M | (m) | $34.56M | (m) | -2764.88% |
| 2018-06-30 | $-54.93M | $2.00M | (m) | $33.01M | (m) | -2749.30% |
| 2018-03-31 | $-59.71M | $1.79M | (m) | $32.38M | (m) | -3339.26% |
| 2017-12-31 | $-61.92M | $1.92M | (m) | $30.88M | (m) | -3220.12% |
| 2017-09-30 | $-61.68M | $1.95M | (m) | $30.30M | (m) | -3167.90% |
| 2017-06-30 | $-55.72M | $1.90M | (m) | $27.86M | (m) | -2931.14% |
| 2017-03-31 | $-48.49M | $1.90M | (m) | $26.72M | (m) | -2546.69% |
| 2016-12-31 | $-43.33M | $1.89M | (m) | $27.07M | (m) | -2296.03% |
| 2016-09-30 | $-41.13M | $1.81M | (m) | $26.62M | (m) | -2269.81% |
| 2016-06-30 | $-43.06M | $1.76M | (m) | $29.20M | (m) | -2441.33% |
| 2016-03-31 | $-41.59M | $1.78M | (m) | $28.96M | (m) | -2334.06% |
| 2015-12-31 | $-38.20M | $1.75M | (m) | $26.61M | (m) | -2182.69% |
| 2015-09-30 | $-35.47M | $1.82M | (m) | $24.87M | (m) | -1949.92% |
| 2015-06-30 | $-31.07M | $1.53M | (m) | $21.09M | (m) | -2026.81% |
| 2015-03-31 | $-27.38M | $1.17M | (m) | $18.64M | (m) | -2338.34% |
| 2014-12-31 | $-27.09M | $772.00K | (m) | $18.88M | (m) | -3509.59% |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $-16.67M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-12.90M | (m) | (m) | $10.52M | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-13.67M | $10.00K | (m) | $11.54M | (m) | -136710.00% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |